Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabin Inactivated Poliovirus Vaccine (Vero Cell) '2+1' Schedule in Infants
NCT03822767Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jun 2018
- Primary completion
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Sabin strain inactivated poliovirus vaccine in poliomyelitis (2 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Type I neutralizing antibody seroconversion rate after primary immunization at 30 days and Type III neutralizing antibody seroconversion rate after primary immunization at 30 days. Started Jun 2018; status: completed.
02
Drugs
Sabin strain inactivated poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT03822767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822767.